Sickle cell disease in Nigeria
Nigeria’s sickle cell disease evidence includes national burden models and research using genotypes measured in a household survey. Screening initiatives and support services add a distinct national context. Sickle cell trait, disease at birth and people living with the disease must be counted separately. [1] [2] [3]
Dr. Fitsum Admasu Tinsae
General Medicine, Public Health, Digital Health
Medical review applies to the clinical background reproduced from our sickle cell disease guide.
Clinical background
SCD is inherited and present from birth. A person's genotype is the inherited combination of hemoglobin variants: HbSS is commonly called sickle cell anemia, while HbSC disease and sickle beta-thalassemia are other forms. Sickle cell trait is different. It is a carrier state with one sickle hemoglobin gene and usually does not produce the clinical syndrome of SCD. [1] [2]
Sickle cell disease data in Nigeria
Births with sickle-cell disease
179,000 affected live birthsNigeria, 2021
Population: Live births; both sexes
Age: Newborns
Sex: All sexes
Denominator: Not applicable — absolute count
Uncertainty: 95% UI 138,000–224,000
Method: GBD 2021 model: birth incidence, all-age prevalence, cause-specific mortality and total mortality among people with sickle-cell disease
People living with sickle-cell disease
2,590,000 peopleNigeria, 2021
Population: All ages; both sexes
Age: All ages
Sex: All sexes
Denominator: Not applicable — absolute count
Uncertainty: 95% UI 2,090,000–3,220,000
Method: GBD 2021 model: birth incidence, all-age prevalence, cause-specific mortality and total mortality among people with sickle-cell disease
Sickle-cell disease birth incidence
2,290 per 100,000 live birthsNigeria, 2021
Population: Live births; both sexes
Age: Newborns
Sex: All sexes
Denominator: Live births
Uncertainty: 95% UI 1,760–2,870
Method: GBD 2021 model: birth incidence, all-age prevalence, cause-specific mortality and total mortality among people with sickle-cell disease
Model-estimated birth prevalence of HbSS
1.21 % of live birthsNigeria, 2018
Population: Birth prevalence inferred from 11,186 tested children aged 6–59 months in 7,411 households
Age: At birth (modelled)
Sex: Both sexes
Denominator: Modelled live births; inferred from allele frequencies in the 2018 child survey
Uncertainty: 95% CI: 1.09–1.37
Method: Hardy–Weinberg assumption near birth applied to nationally sampled 2018 NDHS genotypes
Interpretation: Model-estimated birth prevalence, not observed newborn-screening prevalence; do not equate with all-age GBD prevalence or infer a time trend.
Model-estimated birth prevalence of HbSC
0.24 % of live birthsNigeria, 2018
Population: Birth prevalence inferred from 11,186 tested children aged 6–59 months in 7,411 households
Age: At birth (modelled)
Sex: Both sexes
Denominator: Modelled live births; inferred from allele frequencies in the 2018 child survey
Uncertainty: 95% CI: 0.19–0.31
Method: Hardy–Weinberg assumption near birth applied to nationally sampled 2018 NDHS genotypes
Interpretation: Model-estimated birth prevalence, not observed newborn-screening prevalence; do not equate with all-age GBD prevalence or infer a time trend.
Sickle cell disease burden in Nigeria
The GBD 2021 study estimates 2,590,000 people living with sickle cell disease and 179,000 affected live births in Nigeria in 2021. The corresponding birth incidence is 2,290 per 100,000 live births. These source-rounded estimates include uncertainty intervals and are not registry totals. [1]
Genotype research and national estimates
A separate analysis of the 2018 Nigeria Demographic and Health Survey used test results from 11,186 children aged 6–59 months in 7,411 households. It estimated birth prevalence of 1.21% for HbSS and 0.24% for HbSC, using an assumption about genetic frequencies near birth. These are inferred birth estimates, not direct measurements in newborns. [2]
The GBD and NDHS-based analyses differ in model, genotype scope, reference period and denominator. Their estimates are kept in separate groups and do not show a time trend. A carrier or trait estimate must not be presented as the number of people with sickle cell disease. [1] [2]
Screening and national policy
In June 2026 the federal government described newborn screening implementation in selected primary and secondary facilities in Lagos, Kano and the Federal Capital Territory, with CHAI support. It also described integration of sickle cell services into primary healthcare and Nigeria-PEN. This documents the stated programme scope, rather than universal screening coverage. [3]
The health ministry lists a second edition of its national sickle cell disease guideline. The link below leads to the official publication catalogue; treatment decisions remain part of individual clinical care. [4]
Support and service information
Sickle Cell Foundation Nigeria describes newborn-screening support for primary and secondary facilities and genetic counselling at its National Sickle Cell Centre and associated clinics or clubs. Its programme page states that counselling requires prior appointments. The provider’s own page is the source for current arrangements. [5]
Organizations and official resources
- Federal Ministry of Health and Social Welfare
- World Health Organization
- Federal health ministry: national guidelines
Official catalogue including the second-edition sickle cell disease guideline.
- Sickle Cell Foundation Nigeria programmes
Provider information on screening support and counselling.
Common questions
Frequently asked questions
The June 2026 government statement describes implementation in selected facilities in Lagos, Kano and FCT. It is not evidence that every newborn or facility in Nigeria is covered. [3]
Sources
- GBD 2021 sickle-cell disease — original appendix, Tables S9 and S13 — GBD 2021 Sickle Cell Disease Collaborators
- Child mortality from sickle cell disease in Nigeria: a model-estimated, population-level analysis of data from the 2018 DHS — Nnodu et al., The Lancet Haematology
- FG reaffirms commitment to closing sickle cell survival gap — Federal Ministry of Information and National Orientation, reporting FMoHSW
- Public Health Policies: national sickle cell and hypertension guidelines — Federal Ministry of Health and Social Welfare
- Our Programmes — Sickle Cell Foundation Nigeria